HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat

GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides.

By FierceBiotech · May 7, 2026 · via FierceBiotech
GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Bayer Buys Perfuse for $2.4B, Targeting Next-Generation Eye Disease Therapy
DealsBriefing
Bayer Buys Perfuse for $2.4B, Targeting Next-Generation Eye Disease Therapy
The $300M upfront deal gives Bayer control of PER-001, a midphase implant for glaucoma and diabetic retinopath…
May 7, 2026
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
DealsSTAT News ↗
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1…
May 7, 2026
A new company rises from the ashes of Purdue Pharma
DealsPharmaVoice ↗
A new company rises from the ashes of Purdue Pharma
Knoa Pharma will still sell the opioid medications that triggered a national crisis, but with guardrails.…
May 6, 2026